An Overview of Chikungunya Virus Infection
NEW MICROBIOLOGICA, 36, 211-227, 2013
Chikungunya virus infection: an overview
Claudia Caglioti, Eleonora Lalle, Concetta Castilletti, Fabrizio Carletti,
Maria Rosaria Capobianchi, Licia Bordi
Laboratory of Virology, “L. Spallanzani” National Institute for Infectious Diseases, Rome, Italy
SUMMARY
Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus belonging to the Togaviridae family, first isolated in Tanzania in 1952. The main vectors are mosquitoes from the Aedes species. Recently, the establishment of an envelope mutation increased infectivity for A. albopictus. CHIKV has recently re-emerged causing millions of infections in countries around the Indian Ocean characterized by climate conditions favourable to high vector density. Importation of human cases to European regions with high density of suitable arthropod vectors (such as A. albopictus) may trigger autochthonous outbreaks. The clinical signs of CHIKV infection include non-specific flu-like symptoms, and a characteristic rash accompanied by joint pain that may last for a long time after the resolution of the infection. The death rate is not particularly high, but excess mortality has been observed in concomitance with large CHIKV outbreaks. Deregulation of innate defense mechanisms, such as cytokine inflammatory response, may participate in the main clinical signs of CHIKV infection, and the establishment of persistent (chronic) disease. There is no specific therapy, and prevention is the main countermeasure. Prevention is based on insect control and in avoiding mosquito bites in endemic countries. Diagnosis is based on the detection of virus by molecular methods or by virus culture on the first days of infection, and by detection of an immune response in later stages. CHIKV infection must be suspected in patients with compatible clinical symptoms returning from epidemic/endemic areas. Differential diagnosis should take into account the cross-reactivity with other viruses from the same
Chikungunya virus infection: an overview
Claudia Caglioti, Eleonora Lalle, Concetta Castilletti, Fabrizio Carletti,
Maria Rosaria Capobianchi, Licia Bordi
Laboratory of Virology, “L. Spallanzani” National Institute for Infectious Diseases, Rome, Italy
SUMMARY
Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus belonging to the Togaviridae family, first isolated in Tanzania in 1952. The main vectors are mosquitoes from the Aedes species. Recently, the establishment of an envelope mutation increased infectivity for A. albopictus. CHIKV has recently re-emerged causing millions of infections in countries around the Indian Ocean characterized by climate conditions favourable to high vector density. Importation of human cases to European regions with high density of suitable arthropod vectors (such as A. albopictus) may trigger autochthonous outbreaks. The clinical signs of CHIKV infection include non-specific flu-like symptoms, and a characteristic rash accompanied by joint pain that may last for a long time after the resolution of the infection. The death rate is not particularly high, but excess mortality has been observed in concomitance with large CHIKV outbreaks. Deregulation of innate defense mechanisms, such as cytokine inflammatory response, may participate in the main clinical signs of CHIKV infection, and the establishment of persistent (chronic) disease. There is no specific therapy, and prevention is the main countermeasure. Prevention is based on insect control and in avoiding mosquito bites in endemic countries. Diagnosis is based on the detection of virus by molecular methods or by virus culture on the first days of infection, and by detection of an immune response in later stages. CHIKV infection must be suspected in patients with compatible clinical symptoms returning from epidemic/endemic areas. Differential diagnosis should take into account the cross-reactivity with other viruses from the same
References: ROSSMANN M.G., SRINIVAS R., NABEL G.J. (2010). A VLP vaccine for epidemic Chikungunya virus protects nonhuman primates against infection MISHRA A.C. (2007). Genetic divergence of Chikungunya viruses in India (1963-2006) with special reference to the 2005-2006 explosive epidemic. J. Gen. Virol. 88, 1967-1976. BLACKBURN N.K., BESSELAAR T.G., GIBSON G. (1995). CAPOBIANCHI M.R. (2008). Presence of the A226V mutation in autochthonous and imported Italian CAPOBIANCHI M.R. (2011). Chikungunya virus isolates with/without A226V mutation show different sensitivity to IFN-α, but similar replication kinetics in non human primate cells. New Microbiol. (1983). Chikungunya virus infection. A retrospective study of 107 cases. S. Afr. Med. J. 63, 313-315. BRIGHTON S.W. (1984). Chloroquine phosphate treatment of chronic Chikungunya arthritis: an open pilot study. S. Afr. Med. J. 66, 217-218. CASTILLETTI C. (2007). Rapid detection and quantification of Chikungunya virus by a one-step reverse transcription polymerase chain reaction real-time assay. Am. J. Trop. Med. Hyg. 77, 521-524. GHOSAL S.R., MUTHUMANI K., VIJAYACHARI P. (2011). CHARREL R., DE LAMBALLERIE X. (2008). Chikungunya in north-eastern Italy: a consequence of seasonal synchronicity CHATTERJEE S.N., SARKAR J.K. (1965b). Electron microscopic studies of suckling mouse brain cells infected with Chikungunya virus. Indian J. Exp. Biol. CHO B., KIM J., CHO J.E., JEON B.Y., PARK S. (2008). Chikungunya disease. J. Virol. Methods. 154, 154159. Y.S., NG L.F. (2011). Persistent arthralgia induced by Chikungunya virus infection is associated with LECUIT M. (2008). A mouse model for Chikungunya: young age and inefficient Type-I interferon signalling are risk factors for severe disease (2009). Prophylaxis and therapy for Chikungunya virus infection CUI F., RAYMOND M., QIAO C.L. (2006). Insecticide resistance in vector mosquitoes in China. Pest. Manag. Sci. 62, 1013-1022. Chikungunya virus, Réunion Island, 2010. Emerg. DESSAIN S.K., ADEKAR S.P., BERRY J.D. (2008). Exploring the native human antibody repertoire to create an-